Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Merck Kgaa (MKGAF)

Merck Kgaa (MKGAF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 20,161,752
  • Shares Outstanding, K 129,242
  • Annual Sales, $ 22,721 M
  • Annual Income, $ 3,056 M
  • 60-Month Beta 0.93
  • Price/Sales 0.89
  • Price/Cash Flow 3.04
  • Price/Book 0.73
Trade MKGAF with:
  • Price/Earnings ttm 19.02
  • Earnings Per Share ttm 8.20
  • Most Recent Earnings $1.99 on 03/07/24
  • Latest Earnings Date 05/08/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 1.96
  • Growth Rate Est. (year over year) +50,869.39%

Price Performance

See More
Period Period Low Period High Performance
1-Month
152.0500 +5.56%
on 04/22/24
180.4300 -11.04%
on 04/01/24
-10.7300 (-6.27%)
since 03/22/24
3-Month
152.0500 +5.56%
on 04/22/24
180.6800 -11.17%
on 03/22/24
-2.9450 (-1.80%)
since 01/23/24
52-Week
143.4630 +11.88%
on 10/30/23
186.4100 -13.90%
on 06/12/23
-18.9950 (-10.58%)
since 04/21/23

Most Recent Stories

More News
Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates

Xencor (XNCR) delivered earnings and revenue surprises of -36% and 1.10%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

XNCR : 18.37 (+0.88%)
MKGAF : 160.5050 (+2.89%)
Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Misses Revenue Estimates

Relay Therapeutics, Inc. (RLAY) delivered earnings and revenue surprises of -11.43% and 42.49%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

RLAY : 5.90 (-0.84%)
MKGAF : 160.5050 (+2.89%)
Profound Medical (PROF) Moves 9.4% Higher: Will This Strength Last?

Profound Medical (PROF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term....

PROF : 7.70 (-0.77%)
MKGAF : 160.5050 (+2.89%)
Bears are Losing Control Over Merck KGaA (MKGAF), Here's Why It's a 'Buy' Now

Merck KGaA (MKGAF) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall...

MKGAF : 160.5050 (+2.89%)
BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Tops Revenue Estimates

BioCryst (BCRX) delivered earnings and revenue surprises of 28.13% and 3.23%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

BCRX : 4.38 (-0.68%)
MKGAF : 160.5050 (+2.89%)
Consumer Price Inflation Really Matters

What CPI index groups should you consult?

MKGAF : 160.5050 (+2.89%)
EC : 11.73 (+1.38%)
BDORY : 10.4900 (-0.76%)
The Zacks Analyst Blog Highlights Banco Do Brasil, Merck KGaA and Ecopetrol

Banco Do Brasil, Merck KGaA and Ecopetrol are included in this Analyst Blog.

MKGAF : 160.5050 (+2.89%)
EC : 11.73 (+1.38%)
BDORY : 10.4900 (-0.76%)
Syntropy Joins MITRE’s Mission to Unlock the Power of Real-World Data for Cancer Research and Treatment

Syntropy , a technology company specializing in healthcare data integration and collaboration solutions, today announced it is joining forces with MITRE to provide data integration support for the mCODEâ„¢...

MKGAF : 160.5050 (+2.89%)
PLTR : 21.64 (+3.20%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Merck is a global pharmaceutical and chemical company. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining...

See More

Key Turning Points

3rd Resistance Point 160.5050
2nd Resistance Point 160.5050
1st Resistance Point 160.5050
Last Price 160.5050
1st Support Level 160.5050
2nd Support Level 160.5050
3rd Support Level 160.5050

See More

52-Week High 186.4100
Fibonacci 61.8% 170.0042
Fibonacci 50% 164.9365
Last Price 160.5050
Fibonacci 38.2% 159.8687
52-Week Low 143.4630

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar